CN102218079A - Biological colloid dispersant used for wound-protection and its preparation method - Google Patents
Biological colloid dispersant used for wound-protection and its preparation method Download PDFInfo
- Publication number
- CN102218079A CN102218079A CN 201110147723 CN201110147723A CN102218079A CN 102218079 A CN102218079 A CN 102218079A CN 201110147723 CN201110147723 CN 201110147723 CN 201110147723 A CN201110147723 A CN 201110147723A CN 102218079 A CN102218079 A CN 102218079A
- Authority
- CN
- China
- Prior art keywords
- wound
- dispersant
- biocolloid
- silver ion
- ion powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a biological colloid dispersant used for wound-protection and its preparation method, which belongs to the technical field of medical surgical drugs. The invention is characterized in that every 1000g weight of a finished product dispersant comprises: 0.12 to 4g of ultrafine silver ion powder, 0.06 to 0.44g of sodium alginate, 0.5 to 1g of tribasic acid, 14.5 to 16g of osmotic agent, 0.4 to 0.8g of tartrate and the balance of pure water, wherein: the tribasic acid is any one type of phosphoric acid or citric acid, the osmotic agent is hydrogen peroxide. The invention has the advantages of security, stability and environmental protection performance; the invention has the ideal penetration effect, which is used for shortening the healing time of wound as well as the treatment period; the biological colloid dispersant used for wound-protection has the advantages of no side effect on patients, no abnormal odor and no sensitization; the preparation method has the merits of less process step and no harsh condition, which can adopt a mass production requirement.
Description
Technical field
The invention belongs to medical surgery practical technique field, be specifically related to a kind of wound of protecting and use the biocolloid dispersant, and relate to this and protect the preparation method of wound, be applicable to infection control and promotion wound healing the body surface wound surface with the biocolloid dispersant.
Background technology
The description page 1 that is called Wound-protection liquid and preparation method thereof in the Granted publication CN100560057C that proposes by the applicant and name to the narration of page 2 the 1st row, to causing of generally acknowledging both at home and abroad such as the situation by burn and open wound surface the traumatic infection medication---existing 3 shortcomings of sulfadiazine silver cream (claiming ointment) or outstanding agent have been done objective appraisal.And for example CN1090905C (powerful disinfectant), CN1134213C (preparation method of bactericide containing silver), CN1262101A (silver ion disinfectant and preparation method thereof) and CN1110557A existing defectives such as (silver nitrate ointments) have also been done evaluation strictly according to the facts to prior art.
Though the technical scheme of the aforesaid CN100560057C that is promptly proposed by the applicant has 4 technique effects that Instructions Page 3 the 12nd to 17 row is concluded, but owing to used gelatin in the prescription, thereby security of products, stability and the feature of environmental protection are not enough to abundant guarantee.As everyone knows, the definition of medical gelatin (English name is gelatin) is: the water soluble protein mixture is that collagen in the bone, skin, ligament, tendon of animal is through acid or alkali partial hydrolysis or boil in water and produce.That is to say that the medical gelatin source is from animal.Yet in recent years, bovine spongiform encephalopathy, bird flu, foot and mouth disease and reproductive and respiratory syndrome or the like take place frequently, if in a single day medical gelatin has used aforementioned bone, skin of this animal in spite of illness etc., so aforesaid three property are that safety, stability and the feature of environmental protection do not have collateral security.Given this, U.S. FDA has proposed the occupation rate of plant gum in market and has been not less than 80% requirement, uses the disadvantage of avoiding aforementioned employing animal gelatin.Moreover be difficult in the guarantee phase in 2 years, keep reliably stable as medical animal gelatin, the situation that does not promptly go bad.
In view of above-mentioned prior art, the applicant has done actively and good try has found the way that overcomes foregoing problems, and technical scheme described below produces under this background.
Summary of the invention
Task of the present invention is to provide a kind of and helps to guarantee safety, help guaranteeing stability and be of value to and embody the feature of environmental protection and have excellent permeation and use and promote the wound surface quickly-healing and improve healing effect and protect wound biocolloid dispersant to what the patient can not produce untoward reaction and non-stimulated, free from extraneous odour and not have sensitization.
Task of the present invention also is to provide a kind of preparation method of protecting wound usefulness biocolloid dispersant, and this method processing step is terse, preparation condition is not harsh and can realize industrial amplification production and can ensure comprehensive embodiment of protecting the technique effect of creating usefulness biocolloid dispersant.
Task of the present invention is finished like this, a kind of wound biocolloid dispersant that protects, be characterised in that in the finished product dispersant of every 1000g weight and comprise: ultra-fine silver ion powder body 0.12-0.4g, sodium alginate 0.06-0.44g, ternary acid 0.5-1g, penetrating agent 14.5-16g, tartaric acid 0.4-0.8g, surplusly be pure water, wherein: described ternary acid is any one in phosphoric acid, the citric acid, and described penetrating agent is a hydrogen peroxide.
In a specific embodiment of the present invention, described pure water is deionized water or distilled water.
In another specific embodiment of the present invention, described sodium alginate is to belong to add alkaline extraction in the Thallus Laminariae (Thallus Eckloniae) of Brown algae plant category and be the polysaccharide carbohydrate of sodium alginate through the main constituent that processing and refining forms.
In another specific embodiment of the present invention, described tartaric acid is the tartaric acid of SILVER REAGENT.
In another specific embodiment of the present invention, the purity of described deionized water and distilled water is 0.1-0.16 μ s/cm.
The preparation method of creating with the biocolloid dispersant of protecting provided by the invention may further comprise the steps:
A) with stirring evenly in the ultra-fine silver ion powder body adding pure water, obtain silver ion powder body liquid;
B) ternary acid is joined carry out acidification in the silver ion powder body liquid and regulate pH value, obtain the silver ion powder body mixed liquor after the acidification, described ternary acid is phosphoric acid or citric acid;
C) tartaric acid is joined in the pure water stir, obtain tartaric acid solution;
D) tartaric acid solution is joined in the silver ion powder body mixed liquor after the acidification and stir evenly, obtain stand-by liquid;
E) sodium alginate is added heating for dissolving and stirring in the pure water, add penetrating agent again and continue to stir, obtain stabilizing agent;
F) stand-by liquid is joined in the stirred vessel that fills pure water stir, add stabilizing agent then and continue to stir, and regulate pH value, then leave standstill, filter and fill, obtain finished product and protect wound biocolloid dispersant.
Also have in the specific embodiment step B of the present invention) described in processing time of acidification be 15-40min, described pH value is 1.5-2.
More of the present invention and in specific embodiment, step C) mixing time described in is 15-40min.
The heating-up temperature of the heating in of the present invention and then specific embodiment, step e) is 50-60 ℃, and mixing time is 5-10min, and the mixing time that described continuation is stirred is 5-10min.
Of the present invention again more and in specific embodiment, step F) mixing time that stirs in the stirred vessel described in is 5-10min, and the mixing time that described continuation is stirred is 5-10min, and described adjusting pH value is 3-4; The described time of repose that leaves standstill is 40-60min, and described 100 mesh filter screens that are filtered into filter.
One of advantage of technical scheme provided by the invention, because sodium alginate has been substituted the animal gelatin that the dependence animal obtains in the prior art, thereby have safety, stability and the feature of environmental protection; Two, have ideal osmotic effect, porous is killed the antibacterial and the endotoxin at deep layer position to the wound surface deep tissues, and loosening the dissolving of slough, pus piece, clot excreted, and helps to shorten wound healing time; Three, the long-time use can not form obvious medicine film and develop immunity to drugs, and can shorten treatment cycle effectively; Four, without any side effects and product free from extraneous odour, no sensitization to the patient; Five, the method processing step is few, condition is not harsh, can adapt to the mass production requirement.
The specific embodiment
By applicant's following detailed description, especially will help to understand the present invention more by the non-restrictive example explanation that provides, and can be more clear to advantage of the present invention and effect.
Embodiment 1:
A) will for example joining 8g's and be that the deionized water for stirring of 0.1-0.16 μ s/cm is even by commercially available acquisition through the purity that conductivity meter records by the ultra-fine silver ion powder body 0.12g of the 10-50 nanometer of good technology company limited production of intelligence source, Chinese Guangdong province Shenzhen section and sale, used container both can be that the vinyon container also can be a rustless steel container, be able to abundant dissolving until the silver ion powder body, thereby obtain silver ion powder body liquid;
B) phosphoric acid with the 0.5g SILVER REAGENT joins by A) carry out acidification in the resulting silver ion powder body of the step liquid, the time of acidification is 30min, regulates pH1.8, obtains the silver ion powder body mixed liquor after the acidification;
C) will join the 8g deionized water for stirring 20min that purity is similarly 0.1-0.16 μ s/cm by the tartaric acid 0.4g of the SILVER REAGENT of for example producing and selling of commercially available acquisition, obtain tartaric acid solution by Chinese Shanghai reagent one factory;
D) with step C) resulting tartaric acid solution joins by step B) stir in the resulting silver ion powder body mixed liquor after acidification, obtain stand-by liquid;
E) will join in the 10g deionized water by the medical grade sodium alginate 0.06g that for example produces of commercially available acquisition by Chinese Qingdao of Shandong province Qingdao Huanghai Sea bio-pharmaceuticals Co., Ltd, heating for dissolving and stir 5min under 60 ℃ of temperature adds mass percent concentration and is 35% hydrogen peroxide (H again
2O
2) 16g continue to stir 5min, obtains stabilizing agent, the sodium alginate described in this step be belong to add in the Thallus Laminariae (Thallus Eckloniae) of Brown algae plant category alkaline extraction and be the polysaccharide carbohydrate of sodium alginate through the refining main composition that forms;
F) will be by step D) resulting stand-by liquid joins in the stirred vessel of the deionized water that fills 956.92g and stirs 10min, then add by step e) resulting stabilizing agent, continue to stir 10min, regulate pH3, regulating pH value adopts phosphoric acid to regulate, leave standstill 40min then, filter and fill with 100 order nylon yarn drainage screens at last, obtain protecting of 1000g and create with biocolloid dispersant finished product.
The related mixing speed of above steps all is as the criterion with 60-100n/min.
Embodiment 2:
A) will for example joining 10g's and in the purity that conductivity meter records is the distilled water of 0.1-0.16 μ s/cm, stir by commercially available acquisition by the ultra-fine silver ion powder body 0.25g of the 10-50 nanometer of good technology company limited production of intelligence source, Chinese Guangdong province Shenzhen section and sale, used container both can be that the vinyon container also can be a rustless steel container, be able to abundant dissolving until the silver ion powder body, thereby obtain silver ion powder body liquid;
B) phosphoric acid with the 0.8g SILVER REAGENT joins by A) carry out acidification in the resulting silver ion powder body of the step liquid, the time of acidification is 15min, regulates pH1.5, obtains the silver ion powder body mixed liquor after the acidification;
C) will join purity by the tartaric acid 0.6g of the SILVER REAGENT of for example producing and selling of commercially available acquisition and be similarly in the 10g distilled water of 0.1-0.16 μ s/cm and stir 40min, obtain tartaric acid solution by Chinese Shanghai reagent one factory;
D) with step C) resulting tartaric acid solution joins by step B) stir in the resulting silver ion powder body mixed liquor after acidification, obtain stand-by liquid;
E) will join 10g by embodiment 1 described sodium alginate 0.42g and go in the distilled water, heating for dissolving and stir 10min under 50 ℃ of temperature adds mass percent concentration and is 35% hydrogen peroxide (H again
2O
2) 14.5g continuation stirring 10min, obtain stabilizing agent;
F) will be by step D) resulting stand-by liquid joins in the stirred vessel of the distilled water that fills 953.43g and stirs 5min, then add by step e) resulting stabilizing agent, continue to stir 5min, regulate pH4, regulating pH value adopts phosphoric acid to regulate, leave standstill 60min then, filter and fill with 100 order nylon yarn drainage screens at last, obtain protecting of 1000g and create with biocolloid dispersant finished product.All the other are all with the description to embodiment 1.
Embodiment 3:
A) will for example joining 15g's and be that the deionized water for stirring of 0.1-0.16 μ s/cm is even by commercially available acquisition through the purity that conductivity meter records by the ultra-fine silver ion powder body 0.4g of the 10-50 nanometer of good technology company limited production of intelligence source, Chinese Guangdong province Shenzhen section and sale, used container both can be that the vinyon container also can be a rustless steel container, be able to abundant dissolving until the silver ion powder body, thereby obtain silver ion powder body liquid;
B) citric acid with the 1g SILVER REAGENT joins by A) carry out acidification in the resulting silver ion powder body of the step liquid, the time of acidification is 40min, regulates pH2, obtains the silver ion powder body mixed liquor after the acidification;
C) will join the 13g deionized water for stirring 15min that purity is similarly 0.1-0.16 μ s/cm by the tartaric acid 0.8g of the SILVER REAGENT of for example producing and selling of commercially available acquisition, obtain tartaric acid solution by Chinese Shanghai reagent one factory;
D) with step C) resulting tartaric acid solution joins by step B) stir in the resulting silver ion powder body mixed liquor after acidification, obtain stand-by liquid;
E) sodium alginate 0.25g is joined in the 10g distilled water, heating for dissolving and stir 8min under 50 ℃ of temperature adds mass percent concentration and is 35% hydrogen peroxide (H again
2O
2) 13.50g and then stirring 8min, obtain stabilizing agent;
F) will be by step D) resulting stand-by liquid joins in the stirred vessel of the deionized water that fills 946.05g and stirs 8min, then add by step e) resulting stabilizing agent, continue to stir 8min, regulate pH3.5, regulating pH value adopts citric acid to regulate, leave standstill 50min then, filter and fill with 100 order nylon yarn drainage screens at last, obtain protecting of 1000g and create with biocolloid dispersant finished product.All the other are all with the description to embodiment 1.
Embodiment 4:
A) the ultra-fine silver ion powder body 0.18g of 10-50 nanometer is joined 12g's and be that the deionized water for stirring of 0.1-0.16 μ s/cm is even through the purity that conductivity meter records, used container both can be that the vinyon container also can be a rustless steel container, be able to abundant dissolving until the silver ion powder body, thereby obtain silver ion powder body liquid;
B) phosphoric acid with the 0.65g SILVER REAGENT joins by A) carry out acidification in the resulting silver ion powder body of the step liquid, the time of acidification is 22min, regulates pH1.6, obtains the silver ion powder body mixed liquor after the acidification;
C) tartaric acid 0.55g is joined the 10g deionized water for stirring 35min that purity is similarly 0.1-0.16 μ s/cm, obtain tartaric acid solution;
D) with step C) resulting tartaric acid solution joins by step B) stir in the resulting silver ion powder body mixed liquor after acidification, obtain stand-by liquid;
E) sodium alginate 0.30g is joined in the 10g distilled water, heating for dissolving and stir 6min under 58 ℃ of temperature adds mass percent concentration and is 35% hydrogen peroxide (H again
2O
2) 15g continuation stirring 6min, obtain stabilizing agent;
F) will be by step D) resulting stand-by liquid joins in the stirred vessel that fills the 951.32g deionized water and stirs 10min, then add by step e) resulting stabilizing agent, continue to stir 5min, regulate pH3.6, regulating pH value adopts phosphoric acid to regulate, leave standstill 45min then, filter and fill with 100 order nylon yarn drainage screens at last, obtain protecting of 1000g and create with biocolloid dispersant finished product.All the other are all with the description to embodiment 1,
By the foregoing description 1 to 4 resultant of the present invention protect wound with biocolloid dispersant finished product (claiming the treatment group) respectively through the clinical practice of Chinese Shanghai The 2nd Army Medical College attached Changhai hospital burn department and Jiangsu Province's Taizhou City First People's Hospital Department of B urn to the patient, compare with the sulfadiazine silver cream of group in contrast and to have the clinical effectiveness shown in table 1 and the table 2.
Table 1 treatment group and matched group wound healing time (x ± s)
Compare * P＜0.05, * * p＜0.01 with matched group
Table 2: the comparison of healing time
Annotate: compare with matched group
1)P＜0.01;
2=P＜0.05.
Compare with matched group, 1 week, 2 weeks and 3 weeks behind burn, bacterial positive rate obviously reduces (P＜0.05).Burn back residual wound bacterial positive rate reaches 100%,, prolongs bacterial positive rate totally descend (P＜0.05) with treatment time based on staphylococcus aureus.Show that by the bacteria culture evaluation Wound-protection liquid of the present invention all has inhibitory action to bacillus pyocyaneus, escherichia coli and staphylococcus aureus.And treatment group case do not find part and systemic adverse reactions, and the conventional and hepatic and renal function of hematuria does not see have unusually.
As from the foregoing, Wound-protection liquid provided by the present invention has proved its infection control at the body surface face, has promoted to have positive meaning aspect the healing of biography face owing to passed through a large amount of clinical practices.This positive effect mainly is that formulation selection is reasonable, has especially adopted plant glutin (sodium alginate) as stabilizing agent.Plant glutin can contain silver ion, just silver ion is discharged when running into antibacterial, holds antibacterial, destroys its respiratory enzyme, with killing bacteria; Plant glutin is to be the sodium alginate of raw material extraction with Sargassum or Thallus Laminariae (Thallus Eckloniae), and in order to substitute animal gelatin, this is the essential distinction of present patent application scheme and prior art.
Claims (10)
1. one kind is protected wound biocolloid dispersant, it is characterized in that comprising in the finished product dispersant of every 1000g weight: ultra-fine silver ion powder body 0.12-0.4g, sodium alginate 0.06-0.44g, ternary acid 0.5-1g, penetrating agent 14.5-16g, tartaric acid 0.4-0.8g, surplusly be pure water, wherein: described ternary acid is any one in phosphoric acid, the citric acid, and described penetrating agent is a hydrogen peroxide.
2. the wound of protecting according to claim 1 is used the biocolloid dispersant, it is characterized in that described pure water is deionized water or distilled water.
3. the wound of protecting according to claim 1 is used the biocolloid dispersant, it is characterized in that described sodium alginate is to belong to add alkaline extraction in the Thallus Laminariae (Thallus Eckloniae) of Brown algae plant category and be the polysaccharide carbohydrate of sodium alginate through the main constituent that processing and refining forms.
4. the wound of protecting according to claim 1 is used the biocolloid dispersant, it is characterized in that described tartaric acid is the tartaric acid of SILVER REAGENT.
5. the wound of protecting according to claim 2 is used the biocolloid dispersant, and the purity that it is characterized in that described deionized water and distilled water is 0.1-0.16 μ s/ ㎝.
6. as claimed in claim 1 protecting created the preparation method of using the biocolloid dispersant, it is characterized in that may further comprise the steps:
A) with stirring evenly in the ultra-fine silver ion powder body adding pure water, obtain silver ion powder body liquid;
B) ternary acid is joined carry out acidification in the silver ion powder body liquid and regulate pH value, obtain the silver ion powder body mixed liquor after the acidification, described ternary acid is phosphoric acid or citric acid;
C) tartaric acid is joined in the pure water stir, obtain tartaric acid solution;
D) tartaric acid solution is joined in the silver ion powder body mixed liquor after the acidification and stir evenly, obtain stand-by liquid;
E) sodium alginate is added heating for dissolving and stirring in the pure water, add penetrating agent again and continue to stir, obtain stabilizing agent;
F) stand-by liquid is joined in the stirred vessel that fills pure water stir, add stabilizing agent then and continue to stir, and regulate pH value, then leave standstill, filter and fill, obtain finished product and protect wound biocolloid dispersant.
7. preparation method of protecting wound with the biocolloid dispersant according to claim 6 is characterized in that step B) described in processing time of acidification be 15-40min, described pH value is 1.5-2.
8. preparation method of protecting wound with the biocolloid dispersant according to claim 6 is characterized in that step C) described in mixing time be 15-40min.
9. preparation method of protecting wound with the biocolloid dispersant according to claim 6 is characterized in that step e) described in the heating-up temperature of heating be 50-60 ℃, mixing time is 5-10min, the mixing time that described continuation is stirred is 5-10min.
10. preparation method of protecting wound according to claim 6 with the biocolloid dispersant, it is characterized in that step F) described in stirred vessel in the mixing time that stirs be 5-10min, the mixing time that described continuation is stirred is 5-10min, and described adjusting pH value is 3-4; The described time of repose that leaves standstill is 40-60min, and described 100 mesh filter screens that are filtered into filter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110147723 CN102218079A (en) | 2011-06-02 | 2011-06-02 | Biological colloid dispersant used for wound-protection and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110147723 CN102218079A (en) | 2011-06-02 | 2011-06-02 | Biological colloid dispersant used for wound-protection and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102218079A true CN102218079A (en) | 2011-10-19 |
Family
ID=44774950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110147723 Pending CN102218079A (en) | 2011-06-02 | 2011-06-02 | Biological colloid dispersant used for wound-protection and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102218079A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784100A (en) * | 2012-08-03 | 2012-11-21 | 徐广彬 | Medical biocolloid solution for sterilization and preparation method thereof |
| CN107496452A (en) * | 2017-09-27 | 2017-12-22 | 苏州汇涵医用科技发展有限公司 | Biocolloid dispersant and preparation method thereof |
| CN107913288A (en) * | 2017-11-29 | 2018-04-17 | 常州巨久回康医疗科技有限公司 | Silver colloid antimicrobial fluid and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002731A (en) * | 2007-01-14 | 2007-07-25 | 常熟市汇涵医用材料厂 | Wound-protection liquid, and its preparing method |
-
2011
- 2011-06-02 CN CN 201110147723 patent/CN102218079A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002731A (en) * | 2007-01-14 | 2007-07-25 | 常熟市汇涵医用材料厂 | Wound-protection liquid, and its preparing method |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784100A (en) * | 2012-08-03 | 2012-11-21 | 徐广彬 | Medical biocolloid solution for sterilization and preparation method thereof |
| CN102784100B (en) * | 2012-08-03 | 2014-12-17 | 徐广彬 | Medical biocolloid solution for sterilization and preparation method thereof |
| CN107496452A (en) * | 2017-09-27 | 2017-12-22 | 苏州汇涵医用科技发展有限公司 | Biocolloid dispersant and preparation method thereof |
| CN107913288A (en) * | 2017-11-29 | 2018-04-17 | 常州巨久回康医疗科技有限公司 | Silver colloid antimicrobial fluid and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104800261B (en) | A kind of cloves compound mouthwash | |
| CH701627B1 (en) | Process for the preparation of a composition of hypochlorous acid and its uses. | |
| EP1209986A1 (en) | Metal-containing compositions, preparations and uses | |
| CN107308184A (en) | Icodextrin biomaterial and preparation method thereof | |
| CN102218079A (en) | Biological colloid dispersant used for wound-protection and its preparation method | |
| CN102784100B (en) | Medical biocolloid solution for sterilization and preparation method thereof | |
| CN106994132A (en) | A kind of oral cavity disinfection sanitizer | |
| CN100560057C (en) | Wound-protection liquid and preparation method thereof | |
| CN104703486A (en) | Citrate-rich calcium-magnesium supplement and uses thereof | |
| CN101023753A (en) | Oxidation-type disinfecting sterilizing agent and preparing method | |
| CN107913288A (en) | Silver colloid antimicrobial fluid and preparation method thereof | |
| JP5405736B2 (en) | Dialysis aqueous solution | |
| AU2014250176A1 (en) | Composition as auxiliary means for oral medication | |
| JP3535151B1 (en) | Method for producing liquid preparation containing live yeast component and liquid preparation | |
| CN1149059A (en) | Preparation and application of sargassum polysaccharide complex | |
| RU2338516C2 (en) | Ferriferous agent for prevention and treatment of anemia at animals | |
| Nauth-Misir | Case of Gross Overdosage of Soluble Phenytoin | |
| CN111407776A (en) | Active silver ion colloid antibacterial agent and preparation method thereof | |
| CN102846661B (en) | Compound nano-silver emulsifiable paste and preparation method thereof | |
| CN102106813A (en) | Sodium new neohouttuyfonate injection and preparation method and application thereof | |
| JP4573205B2 (en) | Iron colloid preparation | |
| CN102846489A (en) | Polyhexamethyleneguanidine hydrochloride iodine medicine bath liquid and preparation method thereof | |
| CN107468706A (en) | A kind of disinfectant tamed iodine and preparation method thereof | |
| JP2003040783A (en) | Tungstic acid salt or molybdic acid salt and addition product of reishi spore useful as pharmaceutical product and health food | |
| CN107854485A (en) | The medical composition and its use of the various trace elements of injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111019 |